Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)

被引：0
|
作者：
Blauvelt, A. [1 ]
Guttman-Yassky, E. [2 ,3 ]
Hussain, I. [4 ]
Worrell, R. [5 ]
Chen, Z. [6 ]
Mina-Osorio, P. [6 ]
Rossi, A. B. [7 ]
Bansal, A. [6 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Mt Sinai Med Ctr, Icahn Sch Med, New York, NY 10029 USA
[3] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA
[4] Vital Prospects Clin Res Inst PC, Tulsa, OK USA
[5] Sanofi Genzyme, Sydney, NSW, Australia
[6] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[7] Sanofi Genzyme, Cambridge, MA USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2021年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：29 / 31
页数：3
相关论文
共 50 条
  • [1] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, Andrew
    Guttman, Emma
    Hussain, Iftikhar
    Chen, Zhen
    Mina-Osorio, Paola
    Rossi, Ana Beatris
    Bansal, Ashish
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB141 - AB141
  • [2] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, A.
    Guttman-Yassky, E.
    Hussain, I.
    Chen, Z.
    Mina-Osorio, P.
    Rossi, A. B.
    Bansal, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E96 - E96
  • [3] Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
    Blauvelt, Andrew
    Guttman-Yassky, Emma
    Paller, Amy S.
    Simpson, Eric L.
    Cork, Michael J.
    Weisman, Jamie
    Browning, John
    Soong, Weily
    Sun, Xian
    Chen, Zhen
    Kosloski, Matthew P.
    Kamal, Mohamed A.
    Delevry, Dimittri
    Chuang, Chien-Chia
    O'Malley, John T.
    Bansal, Ashish
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) : 365 - 383
  • [4] Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
    Andrew Blauvelt
    Emma Guttman-Yassky
    Amy S. Paller
    Eric L. Simpson
    Michael J. Cork
    Jamie Weisman
    John Browning
    Weily Soong
    Xian Sun
    Zhen Chen
    Matthew P. Kosloski
    Mohamed A. Kamal
    Dimittri Delevry
    Chien-Chia Chuang
    John T. O’Malley
    Ashish Bansal
    [J]. American Journal of Clinical Dermatology, 2022, 23 : 365 - 383
  • [5] Efficacy and safety of dupilumab for up to 1 year in a phase 3 Open-Label Extension (OLE) Trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)
    Blauvelt, A.
    Guttman-Yassky, E.
    Paller, A. S.
    Thaci, D.
    Simpson, E. L.
    Browning, J.
    Bastian, M.
    Chen, Z.
    Delevry, D.
    O'Malley, J. T.
    Bansal, A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 9 - 9
  • [6] Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)
    Blauvelt, Andrew
    Guttman-Yassky, Emma
    Paller, Amy S.
    Simpson, Eric L.
    Browning, John
    Chen, Zhen
    Delevry, Dimittri
    Mahajan, Puneet
    O'Malley, John T.
    Bansal, Ashish
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB97 - AB97
  • [7] Efficacy and safety of dupilumab for up to 1 year in a phase III open-label extension trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled moderate-to-severe atopic dermatitis
    Blauvelt, A.
    Guttman-Yassky, E.
    Simpson, E. L.
    Browning, J.
    Chen, Z.
    Bansal, A.
    O'Malley, J. T.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E116 - E116
  • [8] 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)
    Cork, Michael J.
    Lockshin, Benjamin
    Blauvelt, Andrew
    Chen, Zhen
    Khokhar, Faisal A.
    Bansal, Ashish
    Prescilla, Randy
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB120 - AB120
  • [9] Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with moderate-to-severe atopic dermatitis (AD)
    Cork, M. J.
    Thaci, D.
    Eichenfield, L.
    Arkwright, P. D.
    Bastian, M.
    Chen, Z.
    Delevry, D.
    O'Malley, J. T.
    Bansal, A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 14 - 14
  • [10] LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN A PHASE 3 OPEN-LABEL EXTENSION TRIAL (LIBERTY AD PED-OLE) IN PATIENTS AGED ≥ 6 TO<12 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Cork, Michael J.
    Thaci, Diamant
    Eichenfield, Lawrence F.
    Arkwright, Peter D.
    Chen, Zhen
    Prescilla, Randy
    Delevry, Dimittri
    O'Malley, John T.
    Bansal, Ashish
    [J]. ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 60 - 60
12345